Transcode Therapeutics, Inc. (RNAZ) › Shareholders' EquityTranscode Therapeutics, Inc. (RNAZ) — Shareholders' EquityAnnual figures by fiscal year, from SEC filings.2019: -$1.11M2020: -$3.41M2021: $20.40M2022: $3.24M2023: $1.64M2024: -$2.02M2025: $10.34M$10.34M2019Shareholders' Equity (USD)2025Fiscal YearShareholders' EquityChange YoY2025$10.34M+612.0%2024-$2.02M-223.0%2023$1.64M-49.4%2022$3.24M-84.1%2021$20.40M+698.7%2020-$3.41M-207.1%2019-$1.11M—Other metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesCash & EquivalentsOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per Share